News

Mauna Kea Technologies Expands International Adoption of Cellvizio® for Pancreatic Cystic Lesions with Key Hospital Installations in Spain and the United Arab Emirates

19 November 2026

Centro Médico Teknon in Barcelona, a flagship of Spain’s leading private hospital group Quirónsalud now offers enhanced characterization of pancreatic cysts with Cellvizio 

King’s College Hospital London in Dubai is the first hospital in the MENA region to offer Cellvizio for improved detection of early pancreatic cancer 

These two key installations mark World Pancreatic Cancer Day, addressing one of the world’s deadliest cancers, causing nearly 490,000 deaths1 annually

Paris and Boston, November 19, 2026 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the clinical deployment of Cellvizio® for improved pancreatic cyst characterization at two flagship institutions: Centro Médico Teknon in Barcelona, the first hospital in Spain, and King’s College Hospital London in Dubai, the first hospital in the Middle East and North Africa (MENA) region, marking World Pancreatic Cancer Day. 

As the sixth leading cause of cancer mortality worldwide, with an estimated 531,000 new cases and nearly 490,000 deaths annually1, pancreatic cancer carries a five-year survival rate below 10%2, making quick characterization of pancreatic cystic lesions critical. Although CT and MRI scans incidentally detect pancreatic cysts in 3% to 10% of adults3 (and 10% to 20% over age 704), conventional work-up often falls short: up to 30% of cysts remain indeterminate after endoscopic ultrasound5 and over 50% of fine-needle cytology aspirations are inconclusive6. Consequently, 40% to 78% of pancreatic resections, high-risk major surgeries, are performed unnecessarily on benign cysts, while other patients undergo unnecessary lifelong surveillance7. 

Included in the European Society of Gastrointestinal Endoscopy (ESGE) guidelines8, EUS-nCLE with Cellvizio® resolves this impasse by allowing the endoscopist to pass a microscopic optical probe through the puncture needle in order to visualize the cyst’s cellular lining in real time and thus to differentiate precancerous mucinous lesions from benign cysts with 96% accuracy and to cut unnecessary surgeries by over 40%9.


In Spain, Dr. Gonzalo López Roldán performs the procedure in his practice within ENDOGROUP, the advanced endoscopy unit at Barcelona’s Centro Médico Teknon, a flagship of Quirónsalud (Fresenius-Helios), Spain’s leading private hospital group and Europe’s largest network (58 general hospitals, including 8 university hospitals). In the UAE, following Emirates Drug Establishment (EDE) clearance in May 2026, Dr. Farooq Khan introduces EUS-nCLE at King’s College Hospital Dubai, a flagship branch of the renowned London teaching hospital housing Dubai’s sole liver transplant center and an Endoscopy Center of Excellence integrated with hepato-pancreatobiliary surgery and oncology. Together, these two reference centers open an expansion pathway across interventional endoscopic ultrasound units in Southern Europe and the MENA region.

Dr. Gonzalo López Roldán, gastroenterologist and endoscopist within ENDOGROUP at Centro Médico Teknon, explained: “Sometimes surgery is recommended early because of the potential risk of malignancy, or patients are kept under unnecessary lifelong surveillance because the diagnosis was not taken as far as it could have been when it was needed. Our aim is to adopt, and use appropriately, techniques such as EUS-nCLE with Cellvizio that provide decisive diagnostic information to help us choose the most suitable strategy in each case. We will also be evaluating artificial intelligence analysis of confocal images to identify lesions with high-grade dysplasia or carcinoma at the right time.” 

Dr. Farooq Khan, Consultant Hepatologist, Gastroenterologist and Interventional Endoscopist at King’s College Hospital Dubai, commented: “Conventional imaging often does not give us enough information to determine the nature of an incidentally discovered cyst, whereas examining its lining at a microscopic level during the procedure helps identify patients who need treatment while potentially avoiding unnecessary surgery for benign cysts. In fact, EUS-nCLE has already helped two of our patients who had been under follow-up imaging for several years, enabling us to reach an accurate diagnosis, including a premalignant cyst requiring timely surgery.” 

Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, added: “These first installations of Cellvizio in Spain and across the MENA region mark a key step in the international expansion of our pancreatic cyst franchise. Partnering with leading clinical teams at Centro Médico Teknon within the Quirónsalud group in Barcelona, and at King’s College Hospital in Dubai shortly after our milestone installation in Abu Dhabi for CellTolerance, reflects growing international demand for real-time cellular imaging while building recurring probe utilization across our newest markets.” 

READ THE COMPLETE PRESS RELEASE

Latest News

PANCREATIC CANCER AWARENESS MONTH: UNDERSTANDING CELLVIZIO® IN CLINICAL PRACTICE 

PANCREATIC CANCER AWARENESS MONTH: UNDERSTANDING CELLVIZIO® IN CLINICAL PRACTICE 

Mauna Kea Technologies Announces the Launch of CellTolerance® at Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to Offer the Program 

Mauna Kea Technologies Announces the Launch of CellTolerance® at Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to Offer the Program 

Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates 

Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates 

No results found.